AXIS: axitinib significantly prolonged PFS
versus sorafenib
mPFS months
95% CI
n
1 0
IRC assessment
p
<0.0001 (log‐rank)
Axitinib
Sorafenib
,
6.8
4.7
6.4–8.3
4.6–6.3
361
362
on‐free
.
0.9
0.8
0 7
Stratified HR=0.67
(95% CI 0.56–0.81)
n progressi
.
0.6
0.5
0 4
Proportio
.
0.3
0.2
0 1
Time (months)
0 2
4
6
8 10 12
22 24 26 28
14 16 18 20
.
0.0
PFS by investigator: 8.3 to 5.6 months with axitinib vs sorafenib,
<0.0001
ORR was 19% vs 9% with axitinib and sorafenib, respectively
